id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-E-0020-0007,FDA,FDA-2009-E-0020,Determination of Regulatory Review Period for Purposes of Patent Extension; EOVIST,Notice,N-Notice,2009-08-04T04:00:00Z,2009,8,2009-08-04T04:00:00Z,2009-10-06T03:59:59Z,2009-08-04T17:27:00Z,E9-18527,0,0,0900006480a00871
FDA-2009-E-0020-0006,FDA,FDA-2009-E-0020,Letter from FDA/CDER to the U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2009-07-16T04:00:00Z,2009,7,2009-07-16T04:00:00Z,,2009-07-16T13:09:24Z,,0,0,09000064809f31cc
FDA-2009-E-0020-0005,FDA,FDA-2009-E-0020,U.S. Patent and Tradmark Office to FDA/CDER - Letter,Other,LET-Letter,2009-04-21T04:00:00Z,2009,4,2009-04-21T04:00:00Z,,2009-04-21T18:35:55Z,,0,0,0900006480961b79
FDA-2009-E-0020-0004,FDA,FDA-2009-E-0020,Letter from FDA/CDER to the U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2009-03-06T05:00:00Z,2009,3,2009-03-06T05:00:00Z,,2009-03-06T14:01:28Z,,0,0,09000064808f6b22
FDA-2009-E-0020-0002,FDA,FDA-2009-E-0020,USPTO to FDA/CDER,Other,LET-Letter,2009-01-22T05:00:00Z,2009,1,2009-01-22T05:00:00Z,,2009-03-06T14:00:00Z,,0,0,090000648082a766
FDA-2009-E-0020-0003,FDA,FDA-2009-E-0020,Attachment A,Supporting & Related Material,APP-Application,2009-01-22T05:00:00Z,2009,1,,,2009-01-22T13:39:50Z,,0,0,090000648082a727
FDA-2009-E-0020-0001,FDA,FDA-2009-E-0020,Bayer Schering Pharma Aktiengesellschaft - Patent Term Extension Application,Other,APP-Application,2009-01-22T05:00:00Z,2009,1,2009-01-22T05:00:00Z,,2013-08-11T02:59:28Z,,0,0,090000648082a6e7